Introduction {#Sec1}
============

Japanese encephalitis virus (JEV) causes a serious and potentially life-threatening infection of the central nervous system of which children are the most affected. Although the majority of infections are asymptomatic, the case fatality is estimated at 20--30% in those who develop clinical disease and up to 50% of survivors experience life-long neuropsychiatric sequelae \[[@CR1], [@CR2]\]. There is no specific antiviral treatment for JE infection but with the availability of safe effective vaccines that can be integrated into existing childhood vaccination programs in endemic countries, there is an opportunity to reduce the adverse health and economic burden of JEV disease.

Currently, there are three commercial vaccines licensed for use in several regions of the world \[[@CR3]--[@CR5]\]. This review will focus on the live-attenuated JE-chimeric vaccine \[ChimeriVax™-JE; also known as IMOJEV and JE-CV (Sanofi Pasteur, Lyon, France)\]. It is a safe and effective prophylactic vaccine against JE for adults and children over 12 months of age, and represents a significant advance from the mouse brain-derived inactivated JE vaccine that had been available since 1955. There is emerging evidence that ChimeriVax™-JE is capable of eliciting long-lasting immunity, even after a single dose of vaccine, making this vaccine an attractive option for use in JE endemic regions of the world.

Method {#Sec2}
======

The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. This review was conducted through a MEDLINE search, limited to the English language, from 1980 to June 2013 using the following search terms and filters: Japanese encephalitis, natural history, virology and vaccine. Manual-search of reference list of relevant studies, clinical trials and reviews was also conducted.

Virology of JEV {#Sec3}
---------------

JEV belongs to the family of *Flaviviridae*, genus Flavivirus, and shares antigenic cross-reactivity with other members of the Flavivirus genus including dengue virus, Murray Valley encephalitis virus, Kunjin virus, West Nile Virus and St Louis encephalitis virus. It is an enveloped, spherical virus that contains an 11-kb single stranded, positive-sense RNA genome. The viral genome encodes a single polyprotein that is cleaved into three structural proteins (capsid, membrane and envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The envelope, E, protein is involved in host receptor binding and entry, neurovirulence and tissue tropism, and is the major antigenic determinant of the host immune response \[[@CR6], [@CR7]\].

There are four major genotypes of JEV based on the envelope gene, and each genotype has been shown to have a relatively specific regional geographic distribution. Genotypes I and III predominate in the more temperate regions of Korea, Japan, China, Taiwan, Philippines, northern Thailand and Cambodia. These viruses are often associated with epidemics of JE. In contrast, genotypes II and IV are associated with endemic infection in southern Thailand, Malaysia and Indonesia \[[@CR8]\]. Genotype V was identified in association with an epidemic of encephalitis in Malaysia in 1952 \[[@CR8]\] and has been isolated in the mosquito vector, *Culex tritaeniorhynchus*, in China \[[@CR9]\].

Transmission Cycle of JEV and Geographic Distribution {#Sec4}
-----------------------------------------------------

JEV is transmitted in a zoonotic cycle between mosquitoes, water birds and pigs. The principal mosquito vector is the *Culex* mosquito, in particular, *C tritaeniorhynchus*, an evening- and night-time biting mosquito \[[@CR10]\]. Mosquitoes are zoophilic, feeding on wading birds (herons and egrets) and pigs, which are the primary hosts in the infection cycle. JEV infection causes high-titer viremia in pigs, which are increasingly recognized as the most important ecological reservoir for JE in the amplification and spread of JEV \[[@CR7]\]. Humans are incidental end-hosts in the lifecycle of JEV and not necessary for the maintenance of the viral transmission due to low-titer viremia in humans that is insufficient to infect the biting mosquito vectors.

JEV is widely distributed throughout Asia and the Pacific rim, with peak endemicity centered on equatorial Asia and seasonal epidemics occurring in the more temperate regions of southeast Asia, India, Japan, Korea, Taiwan and mainland China (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11]--[@CR14]\]. In the tropical and subtropical regions of Asia, transmission of JEV occurs year-round, peaking during the rainy season, while in the northern temperate regions, JE follows an epidemic pattern and is more prevalent during and after the monsoon rains in summer and autumn. JE infection in humans has been tracked according to rainfall patterns, mosquito numbers and seroconversion in sentinel animals \[[@CR15]\]. More recently, JEV has been identified in the Torres Strait Islands and in the Cape York Peninsula of Far North Queensland in Australia \[[@CR16]--[@CR18]\] and also in Tibet, formerly believed to be a non-endemic region \[[@CR19]\].Fig. 1Global geographical distribution of Japanese encephalitis. This figure was obtained from the United States Centers for disease control and prevention (CDC) Yellow Book \[[@CR14]\]

Incidence of JE in Endemic Populations and Travelers {#Sec5}
----------------------------------------------------

It has been difficult to accurately determine the incidence of JE infection because the majority of infections are subclinical \[[@CR20]\]. The extent to which measures to control the mosquito vector, improvements in agricultural and commercial animal husbandry practices and JE vaccination programs have impacted on the overall incidence of JE infection has not been accurately quantified. In 2011, the World Health Organization (WHO) surveillance data estimated that the incidence of JE infection was 1.8 per 100,000 persons, approximately 67,900 new cases annually. However, with 75% of cases occurring in children, the annual incidence in those aged 0--14 years was 5.4 per 100,000, 3 times higher than the overall incidence \[[@CR21]\].

The expansion of global travel, tourism and economic opportunities in Asia has seen a large number of travelers from non-endemic regions visiting and living in JEV endemic regions, and this population represents an emerging group at risk of acquiring JE infection \[[@CR22]--[@CR24]\]. The overall risk of acquisition of JE in travelers is difficult to ascertain, as the risk relates directly to activities that increase the likelihood of mosquito bites, including season and duration of travel, travel to rural areas, outdoor activities and accommodation lacking mosquito screens. A recent Australian study of short-term travelers spending \<30 days in endemic regions in Asia during the peak rainy season reported no cases of JE \[[@CR25]\]. In contrast, Hill and co-workers reported an incidence of 0.2 cases per million travelers \[[@CR26]\] while an earlier study in Swiss and British travelers reported an incidence of 1.3 cases per 7.1 million travelers \[[@CR27]\]. Even though the incidence is low, travelers from non-endemic countries have no pre-existing immunity and are at risk of acquiring a potentially devastating neurological infection with permanent sequelae. The need for vaccination must be weighed up against the duration of travel and the nature of activities undertaken.

Clinical Manifestation of JE and Natural History {#Sec6}
------------------------------------------------

Children aged 3--15 years old in endemic areas are highly susceptible to JE infection. The incubation period of JE infection ranges from 5 to 15 days following inoculation from an infected mosquito bite. Symptoms often begin abruptly with a non-specific febrile illness that may be self-limiting, or may progress to aseptic meningitis or encephalitis. Aseptic meningitis with nausea, vomiting headache, nuchal rigidity and photophobia is seen in 5--10% of patients, while encephalitis, the most serious manifestation of JE, is seen in up to 60--75% of patients. Encephalitis follows the febrile prodrome by 2--4 days and is characterized by altered sensorium, motor and behavioral abnormalities. Individuals may also manifest acute flaccid paralysis with areflexia resembling poliomyelitis, seizures and movement disorders, typically choreoathetosis, myoclonus and Parkinsonism \[[@CR1], [@CR2]\]. In those with mild non-neurological disease, clinical improvement coincides with the onset of defervescence. However, the motor deficits, movement, behavioral, psychiatric disorders and learning deficits often persist and may take several decades to improve. These long-term sequelae extend the morbidity of the infection well beyond the acute period and add to the health and economic burden to local communities \[[@CR28]\].

Laboratory Diagnosis of JE Infection {#Sec7}
------------------------------------

Diagnosis of acute JE infection is made by detecting JEV-specific IgM or a fourfold rise in JEV-specific IgG in the serum and cerebrospinal fluid (CSF) by capture enzyme-linked immunosorbent assay (MAC ELISA). JEV-specific IgM antibodies rise rapidly and are detectable in the CSF by day 4 after the onset of symptoms, and by day 7 in the serum, followed by a slower rise in JEV-specific IgG \[[@CR29], [@CR30]\]. By day 30 after primary infection, JEV-specific IgG antibodies are detected in the serum in 100% of individuals. However, in endemic regions, JE antibodies may be confounded by cross-reacting antibodies from other flavivirus infection such as dengue, tick-born encephalitis or from previous vaccination against yellow fever or JE \[[@CR31], [@CR32]\]. A fourfold or greater rise in JE-specific antibodies between acute and convalescent-phase serum 2--4 weeks apart is useful in confirming acute infection and distinguishing from non-JEV flaviviral cross-reacting antibodies. JEV-specific IgM may also be detectable in the CSF and has been associated with a poorer outcome \[[@CR30]\]. JEV-specific neutralizing antibodies can also be determined by the plaque reduction neutralization test (PRNT). However, this is a labor-intensive assay and is usually only available in research and reference laboratories.

Although conventional nucleic acid amplification test of CSF and serum are not used to diagnose acute JE because viremia is short-lived and of low titer, recent advances in the real-time RT-PCR technology using loop-mediated isothermal amplification (RT-LAMP) could see its use in resource-poor settings \[[@CR33]\]. Real-time RT-LAMP is rapid test and easy to perform using a single tube assay with color detection visible to the naked eye. It has a detection limit as low as 0.1 plaque forming units (pfu). Parida et al. \[[@CR34]\] reported a sensitivity and specificity of RT-LAMP of 100% and 86%, respectively, and was able to detect serologically confirmed positive samples missed by conventional RT-PCR. Its utility and advantage over the current serological tests have not yet been determined.

Treatment of JE {#Sec8}
---------------

There are no specific antiviral treatments for JE, and any treatments are largely supportive to control seizures, dystonia, cerebral edema and respiratory support. Clinical trials of interferon α-2a, ribavirin and corticosteroids have failed to show improvement in clinical outcome and are not recommended \[[@CR35]--[@CR37]\]. Prevention of JE by vaccination and vector control measures remains the only enduring options to reduce the incidence of JE.

JE Preventive Vaccine {#Sec9}
---------------------

Until more recently, the prevention of JE infection has relied on the use of an inactivated mouse brain-derived vaccine developed by BIKEN in Japan since 1955 and licensed under the name of JE-VAX (BIKEN, Osaka, Japan). Although it reduced the disease burden in many JE endemic regions, it was associated with severe allergic reactions. Three vaccines have since been developed based on the neuroattenuated strain of JEV, SA14-14-2. Two of the vaccines are live-attenuated vaccines: one developed by Chengdu Institute of Biological Product, People's Republic of China, and the second, the ChimeriVax™-JE vaccine developed by Sanofi Pasteur. The third vaccine (IXIARO^®^; JESPECT^®^ in Australia) is an inactivated Vero cell-derived SA14-14-2 vaccine developed by Intercell Biomedical (Livingston, United Kingdom) and distributed by Novartis Vaccines (Surrey, United Kingdom). Table [1](#Tab1){ref-type="table"} \[[@CR3]--[@CR5], [@CR38], [@CR39]\] summarizes the key features of the inactivated IXIARO^®^ and live-attenuated Chengdu vaccine, while this review will focus on the ChimeriVax™-JE vaccine.Table 1Summary of licensed Japanese encephalitis (JE) vaccinesIXIARO^®^ (Intercell, Livingston, United Kingdom/Novartis vaccines, Surrey, United Kingdom) \[[@CR3], [@CR38]\]CD-JEVAX^®^ (Chengdu biologicals, Chengdu, China) \[[@CR4]\]ChimeriVax^®^ (Sanofi Pasteur, Lyon, France) \[[@CR5], [@CR39]\]Virus strainSA 14-14-2SA 14-14-2SA 14-14-2Cell type for virus propagationVero cellsPrimary hamster kidney cellsVero cellsVaccine formulationFormalin inactivated with aluminum hydroxide; liquidLive attenuated without adjuvant or preservative; lyophilizedLive attenuated without adjuvant or preservative; lyophilizedVaccine schedule≥3 yo: 2 doses of 0.5 ml at day 0 and 28\
2 months--2 yo: 0.25 ml at days 0 and 28^a^Single dose 0.5 ml. Booster may be applicable in toddlers after primary vaccinationSingle dose, 0.5 ml. Booster applicable for primary vaccination in toddlers% Seropositive vaccinees at day 28 post-primary vaccinationAdults: 98%\
Children 1--3 yo: 71%Adults: limited or no data\
Children: 76%Adults: 99%\
Children 12--18 months: 95%Geometric mean titer at day 28 post-primary vaccination (range)Adults: 244 (5--783)\
Children 1--3 yo: 218 (121--395)Adults: No data\
Children age: 133 (11--2,991)^b^Adults: 1,392 (1,156--1,674)\
Children 12--18 months: 214 (168--271)% Seropositive vaccinees at 1 yearAdults: 69%\
Children: limited or no dataAdults: limited or no data\
Children 1--15 yo: 90%^b^Adults: 95%\
Children: 80%^ca^United States Centers for disease control and prevention (CDC) recommendations are adhered to here \[[@CR14]\]^b^Geometric mean titer and seropositivity rate at 4-year post-primary vaccination^c^Children aged 36--42 months at 2-year follow-up

ChimeriVax-JE (JE-CV) {#Sec10}
---------------------

The ChimeriVax™-JE vaccine, also known as IMOJEV^®^ and JE-CV, is a live-attenuated recombinant chimeric virus vaccine based on the live-attenuated yellow fever virus (YFV) vaccine, YFV17D, in which genome sequences encoding the membrane and envelope proteins of YFV have been replaced with the corresponding genomes sequences of the attenuated JEV strain, SA-14-14-2 (Fig. [2](#Fig2){ref-type="fig"}). The ChimeriVax™-JE vaccine expresses the immunogenic envelope protein of JE, but contains the nucleocapsid protein and replication machinery of YFV17D. The ChimeriVax technology was developed by Chambers et al. \[[@CR40]\] at St Louis University (MO, USA) and further developed into the JE-chimeric virus at Acambis (Cambridge, UK) \[[@CR41]\] before being licensed by Sanofi Pasteur.Fig. 2Genomic organization of ChimeriVax™-JE. Genes encoding the prM and E proteins of the live-attenuated yellow fever virus, YF17D, are replaced by the prM and E genes of the attenuated JEV, SA14-14-2 strain. The chimeric virus replicates using the YF17D machinery but expresses the envelope and prM proteins of JEV SA14-14-2 on its external virion. *JE* Japanese encephalitis, *C* core protein gene, *preM* pre-membrane protein gene, *E* envelope protein gene, *NS1-NS5* non-structural protein genes 1--5

Preclinical Testing {#Sec11}
-------------------

The ChimeriVax™-JE vaccine consists of a JEV clone derived by serial passaging of the SA14-14-2 strain in serum-free Vero cell culture. The virus contains a mutation at amino acid 60 of the M protein that confers a capability to propagate at high viral titers without loss of the neuroattenuation phenotype \[[@CR42]\]. Full restoration of neurovirulence to wild-type Nakayama strain required at least four reversions in three different E protein domains, while two simultaneous amino acid reversions only partially restored neurovirulence \[[@CR43]\]. Small animal model studies with intracerebral inoculation of ChimeriVax™-JE into mice and non-human primates (rhesus and cynomolgus monkeys) have demonstrated that ChimeriVax™-JE was less neurovirulent than the parental YFV17D \[[@CR44]\]. Extensive pre-clinical testing of ChimeriVax™-JE also confirmed the stability of the attenuated genotype and phenotype, its robust immunogenicity, the production of low-level viremia in non-human primates and poor infectivity in mosquito vectors \[[@CR45]\].

Immunogenicity and Durability of the Immune Response in Adults {#Sec12}
--------------------------------------------------------------

One of the first human clinical trials (H-040-001) examined the tolerability and immunogenicity of two doses of the ChimeriVax™-JE vaccine compared to the live-attenuated yellow fever vaccine, YF-VAX^®^ (Sanofi Pasteur, Lyon France), in young health adults with and without pre-existing YF immunity \[[@CR46]\]. The ChimeriVax™-JE vaccine was well tolerated and all participants, regardless of prior YF immunity, developed neutralizing antibodies to the vaccine strain that cross-neutralized wild-type JEV.

These findings were confirmed in a subsequent study involving 99 individuals \[[@CR47]\]. In this dose-ranging study, 100% of individuals who received a dose of 3.8 log~10~ pfu developed neutralizing antibodies with a GMT of 201 (95% CI 65--681). Cross-reactive neutralizing antibodies to the wild-type JE strains, Nakayama, Beijing-1 and a Vietnamese 902/97 strain were detected in the sera of vaccine recipients. Previous vaccination with YF-VAX ^®^did not have a negative effect on the development of neutralizing antibody responses to ChimeriVax™-JE.

A strong antibody response was observed after challenging a subset of ChimeriVax™-JE vaccine recipients with a single dose of inactivated mouse brain-derived JE vaccine (Nakayama strain; JE-VAX^®^, BIKEN, Osaka, Japan) \[[@CR47]\]. These individuals developed higher antibody titers against ChimeriVax™-JE than against wild-type strains, demonstrating that the ChimeriVax™-JE vaccine was capable of eliciting a memory immune response.

The durability and efficacy of the neutralizing antibody response to the ChimeriVax™-JE vaccine were assessed in a 5-year follow-up study \[[@CR48]\]. In this study, 202 young healthy participants from non-endemic countries received primary vaccination with a single dose of ChimeriVax™-JE vaccine and were then randomized to receive a booster or no booster dose at 6 months. At one month after primary vaccination, 99% of participants seroconverted and the geometric mean titer (GMT) of neutralizing antibody obtained by PNRT that achieved a 50% reduction on in viral plaques in Vero cell cultures (PRNT~50~) was 317 (95% CI 260--385). At 6 months, 97% (95% CI 93--99) remained seropositive, with a GMT of 151 (95% CI 125--181). In the group randomized to receive the booster vaccine at 6 months, 100% were seropositive 1 month after booster vaccination, with a GMT of 353, comparable to the post-primary vaccination level (95% CI 289--432). After 5 years of follow-up, more than 90% of all participants remained seropositive, with 95% (95% CI 82--99) seropositivity in those who received a single-dose vaccine compared to 97% (95% CI, 85--100) in those who received two doses of the vaccine. Using the Kaplan--Meier decay analysis, 87% (95% CI 78--96) of participants who received a single vaccine and 96% (95% CI 89--100) of participants who received the 2-dose schedule were predicted to be still seropositive at 5-year post-vaccination \[[@CR48]\].

This study also demonstrated that the vaccine-induced antibodies were capable of neutralizing wild-type JEV. Of the 197 participants, at day 28 post-vaccination, 99.5% (95% CI 97--100) had neutralizing antibodies (PRNT~50~ ≥10) to at least one strain from a panel of four wild-type JEV strains consisting of a genotype I isolate from Korea (1991 TVP-8236), a genotype II isolate from Thailand (B1034/8), a genotype III isolate from China (Beijing) and a genotype IV isolate from Indonesia (JKT 9092/TVP-6265). Up to 95% (95% CI 91--98) of the participants neutralized at least three of the four wild-type strains, and 85% (95% CI 80--90) neutralized all four wild-type strains. Of the 46 participants available at 5-year follow-up, cross-neutralizing antibodies were still present in 65% (95% CI 50--79) of single-dose vaccinees compared to 75% (95% CI 58--88) of those who received 2 vaccine doses.

In the pivotal Phase III trial of 820 participants, a head-to-head comparison of ChimeriVax™-JE with the inactivated mouse brain-derived JE vaccine (Nakayama strain), JE-VAX^®^, showed that the immunogenic response to a single dose of ChimeriVax™-JE was statistically non-inferior to the 3-dose regimen of JE-VAX^®^ \[[@CR5]\]. Seroconversion was recorded in 99.1% (95% CI 98--100) of individuals vaccinated with ChimeriVax™-JE, compared to 95% (95% CI 92--97) of those who received JE-VAX^®^. In addition, cross-neutralizing antibodies to the Nakayama strain were present in 81% (95% CI 76--85) of the ChimeriVax™-JE group, compared to 75% (95% CI 70, 80) in the JE-VAX^®^ group \[[@CR5]\].

In a follow-up study, the durability of vaccine-induced antibody was estimated by statistical modeling \[[@CR49]\]. Based on the GMT value at 28-day post-vaccination (GMT 1392 in the ChimeriVax™-JE group), the rate of antibody decline was gradual enough to confer seroprotection for up to 10 years post-vaccination. The median duration of seroprotection was estimated to exceed 20 years, suggesting that booster vaccination in adults may be unnecessary. Furthermore, repeated re-exposure to natural infection in JE endemic areas may provide sufficient natural boosting to maintain protective antibody titers \[[@CR47], [@CR48]\].

The Use of ChimeriVax™-JE in Children {#Sec13}
-------------------------------------

Since the eradication of polio, JE is now one of the most important childhood neurological infections in infants and young children causing permanent and devastating neurological sequelae \[[@CR50]\]. A number of trials have now been conducted in children in JE endemic regions and have reported on the safety, immunogenicity and seroprotection rates after ChimeriVax™-JE vaccination in the pediatric population.

In a phase II study of 300 Thai children aged 2--5 years who had previously received a 2-dose primary vaccination with the mouse brain-derived inactivated JE vaccine, JE-VAX^®^ (JE-VAX^®^ vaccine-primed group), vaccination with ChimeriVax™-JE resulted in seropositivity rates of 100% (95% CI 96--100) \[[@CR51]\]. This compared with 96% (95% CI 92--98) of 200 vaccination-naïve toddlers aged 12--24 months who received their first and only dose of ChimeriVax™-JE. The geometric mean titers, when tested against the ChimeriVax™-JE strain, were 2,634 (95% CI 1,928--3,600) and 281 (95% CI 219--362) in the JE-VAX^®^ vaccine-primed and vaccine naïve groups, respectively. This suggested firstly, previous immunization with a non- ChimeriVax™-JE vaccine could elicit a robust anamnestic response to a different vaccine strain, and secondly, low antibody titers in the vaccine naïve toddlers group may be due to an immature immune system. Cross-neutralizing antibodies to wild-type JE virus were present in 72--81% of the JE-VAX^®^ primed group compared to 3--6% in the vaccine naïve toddlers. In the JE-VAX^®^ vaccine-primed children, 99% of children had seroprotective antibody titers against at least 3 of 4 wild-type JEV, with 89% against 1991-TVP-8236, 89% against B1034/8, 90% against Beijing, and 91% against JKT 9092/TVP-6265. In the vaccine naïve toddlers, 97% demonstrated cross-neutralization against 1991-TVP-8236, 96% against B1034/8, 97% against Beijing, and 70% against JKT 9092/TVP-6265. At 12 months post-vaccination, the seroprotective rates remained high in both groups, 84% and 97% in the 2--5 year old children and 12--24 months old toddlers, respectively, with GMT against the ChimeriVax™-JE strain of 454 and 62 \[[@CR51]\].

In a subsequent Phase III study in Thailand and the Philippines involving 1,200 JE vaccine naïve children aged 12--18 months, the seroconversion rate to a single dose of ChimeriVax™-JE was 95% (95% CI 93--96) with a GMT value of 214 (95% CI 168--271) \[[@CR38]\] against the homologous vaccine strain. In a follow-up study, the effect of booster vaccination with ChimeriVax™-JE in children aged 36--42 months who had received the primary vaccination 2 years prior was reported \[[@CR52]\]. Of the 350 children studied, 80% of primary vaccinees had seroprotective antibodies at study commencement, albeit with low GMT values, 39 (95% CI 34--46). Antibody titers increased by 57-fold at 28 days after the booster vaccine with a GMT value of 2,242 (95% CI 1,913--2,628). One year post-booster, 99% (95% CI 98--100) of children remained seroprotected and recorded GMT values of 596 (95% CI 502--708). In a subgroup of 14/345 children who failed to seroconvert after primary vaccination, all responded to the booster vaccine and recorded GMT values of 290 (95% CI 118--713). A further subgroup of children who were seronegative (PRNT~50~ \< 1:10) 2 years post-primary vaccination also demonstrated a robust response to a booster vaccine. The rapid anamnestic response to a booster vaccination reported here would suggest that there is value in providing a booster vaccine in toddlers who have received primary vaccination. It remains uncertain if a similar immune response to natural infection following primary vaccination in a toddler from an endemic region may be sufficient to protect from infection.

Safety of ChimeriVax™-JE and Interactions with Pre-existing Flavivirus Immunity {#Sec14}
-------------------------------------------------------------------------------

There were no reported serious adverse effects related to the use of ChimeriVax™-JE vaccine in either adults or children from endemic and non-endemic countries, and in particular, no severe neurological events, allergic reactions, anaphylaxis or death. The presence of pre-existing flavivirus immunity including previous vaccination with the live-attenuated YF vaccine did not cause any serious adverse events in ChimeriVax™-JE vaccine recipients \[[@CR46], [@CR47]\].

Overall, vaccine-related reactions were observed in 52.0% (833/1,601, 4,581 events) in those who received the ChimeriVax™-JE vaccine compared to placebo, 50.6% (204/403, 945 events) \[[@CR5]\]. Systemic upset with fever, irritability and localized injection site reactions were the commonest adverse reactions and the reactogenicity of ChimeriVax™-JE was similar to that of a comparator hepatitis A vaccine, Avaxim^®^ 80U (Sanofi Pasteur, Lyon, France) \[[@CR51]\].

Low-level viremia was detected in 5 of 300 children, all of who were asymptomatic \[[@CR47]\]. Short-lived low-level asymptomatic viremia was also seen in some vaccinated adults with a mean peak viraemia 6.6 pfu/ml, a level not expected to cause adverse environmental impact on transmission in mosquito vectors.

Conclusion {#Sec15}
==========

Recent years have seen considerable progress in the refinement of safe and effective vaccines against JE. There are three vaccines with good immunogenicity profile for adults and children, suitable for those in both JE-endemic and non-endemic regions, and which can be integrated into the existing childhood vaccination programs. The novel recombinant chimeric live vaccine, ChimeriVax™-JE, has been shown to be highly immunogenic in both adults and children, with a durable neutralizing antibody titers and robust anamnestic response.
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